Missing content? – Request curation!
Request curation for specific Genes, Variants, or PubMed publications.
Have questions, comments, or suggestions? - Let us know!
Email us at : ckbsupport@jax.org
Profile Name | PALB2 dec exp |
Gene Variant Detail | |
Relevant Treatment Approaches |
Molecular Profile | Indication/Tumor Type | Response Type | Relevant Treatment Approaches | Therapy Name | Approval Status | Evidence Type | Efficacy Evidence | References |
---|---|---|---|---|---|---|---|---|
PALB2 dec exp | triple-receptor negative breast cancer | sensitive | SN30000 | Preclinical | Actionable | In a preclinical study, knockdown of PALB2 enhanced growth inhibition by SN30000 in triple-negative breast cancer cell lines in culture (PMID: 25193512). | 25193512 | |
PALB2 dec exp | triple-receptor negative breast cancer | sensitive | PR-104 | Preclinical | Actionable | In a preclinical study, knockdown of PALB2 enhanced growth inhibition by PR-104 in triple-negative breast cancer cell lines in culture (PMID: 25193512). | 25193512 | |
PALB2 dec exp | triple-receptor negative breast cancer | sensitive | Evofosfamide | Preclinical | Actionable | In a preclinical study, knockdown of PALB2 enhanced growth inhibition by Evofosfamide (TH-302) in triple-negative breast cancer cell lines in culture (PMID: 25193512). | 25193512 | |
PALB2 dec exp | triple-receptor negative breast cancer | sensitive | Chlorambucil | Preclinical | Actionable | In a preclinical study, knockdown of PALB2 enhanced growth inhibition by Ambochlorin (chlorambucil) in triple-negative breast cancer cell lines in culture (PMID: 25193512). | 25193512 | |
PALB2 dec exp | triple-receptor negative breast cancer | sensitive | Cisplatin | Preclinical | Actionable | In a preclinical study, knockdown of PALB2 enhanced growth inhibition by Platinol (cisplatin) in triple-negative breast cancer cell lines in culture (PMID: 25193512). | 25193512 |